Loading…
Reported covered position: Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Colorado Outdoor Recreation and Economy Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act.
Colorado Outdoor Recreation and Economy Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Source: Senate LDA
| CURIA GLOBAL, INC. (FORMERLY KNOWN AS ALBANY MOLECULAR RESEARCH, INC.) | 13 | 2020–2023 |
| THE COALITION FOR THE ADVANCEMENT OF RESEARCH AND INNOVATION IN TRAUMA (CARIT) | 11 | 2021–2023 |
| ELUSYS THERAPEUTICS INC | 9 | 2024–2026 |
| EMERJA, INC. (FORMERLY KNOWN AS WHEEL BIOLOGY, INC.) | 9 | 2020–2021 |
| MIND MEDICINE INC. | 9 | 2024–2026 |
| LIFESCIENCE LOGISTICS | 8 | 2024–2025 |
| REVAGENIX, INC. | 8 | 2025–2026 |
| ROIVANT SCIENCES, INC. | 8 | 2020–2021 |
| PSYCHEDELIC MEDICINE COALITION | 7 | 2023–2024 |
| CENTIVAX | 6 | 2020–2021 |
| COHERUS BIOSCIENCES | 6 | 2023–2024 |
| LYSOVANT SCIENCES INC. | 6 | 2020–2021 |
| ADAPTIVE PHAGE THERAPEUTICS | 5 | 2022 |
| PARATEK PHARMACEUTICALS, INC. | 5 | 2023 |
| CHILD GENETIC SCREENING ALLIANCE | 4 | 2026 |
| CORNERSTONE GOVERNMENT AFFAIRS OBO TEXAS MEDICAL CENTER | 4 | 2023 |
| NABRIVA THERAPEUTICS US, INC. | 4 | 2020 |
| OCUGEN, INC. | 4 | 2023 |
| UNITED STATES PHARMACOPEIAL CONVENTION | 4 | 2020 |
| PHLOW CORPORATION | 3 | 2020 |
| PKX BIO | 3 | 2026 |
| PhaseBio Pharmaceuticals, Inc. | 3 | 2020 |
| FOUNDATION FIGHTING BLINDNESS | 2 | 2023 |
| SPECGX, LLC | 2 | 2020 |
Colorado Outdoor Recreation and Economy Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act.
Colorado Outdoor Recreation and Economy Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act.
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act.
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act.
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
seek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
eek approval for regulatory support; HR3437; Loans Act
LOANS for Biomedical Research Act
Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) · Firm: THE CONAFAY GROUP, LLC
Seek approval for regulatory support; HR3437; Loans Act
2026 · third_quarter · Q3
Support for Genetic Screening.
Support for Genetic Screening.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PKX BIO via THE CONAFAY GROUP, LLC
2026 · third_quarter · 3T
Advocate for funding for research and development for pain solutions.
Advocate for funding for research and development for pain solutions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PKX BIO via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Advocate for funding for research and development for pain solutions.
Advocate for funding for research and development for pain solutions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHILD GENETIC SCREENING ALLIANCE via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Support for Genetic Screening.
Support for Genetic Screening.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PKX BIO via THE CONAFAY GROUP, LLC
2026 · second_quarter · RR
Advocate for funding for research and development.
Advocate for funding for research and development.
CHILD GENETIC SCREENING ALLIANCE via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Support for Genetic Screening.
Support for Genetic Screening.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY27 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CHILD GENETIC SCREENING ALLIANCE via THE CONAFAY GROUP, LLC
2026 · first_quarter · RR
Support for Genetic Screening.
Support for Genetic Screening.
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · 4T
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2025 · third_quarter · 3T
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Seek approval for regulatory support; FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Seek approval for regulatory support; FY26 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REVAGENIX, INC. via THE CONAFAY GROUP, LLC
2025 · first_quarter · RR
Opportunities to promote antimicrobial drug development.
Opportunities to promote antimicrobial drug development.
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY25 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MIND MEDICINE, INC. via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Advocacy for medical countermeasure funding and support.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Seek approval for regulatory support; FY25 appropriations; education about the microbiome and federal research opportunities. FDA reform.
Seek approval for regulatory support; FY25 appropriations; education about the microbiome and federal research opportunities. FDA reform.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
MIND MEDICINE, INC. via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · RR
Education and advocacy for novel brain health treatments.
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Seek approval for regulatory support; FY25 appropriations; education about the microbiome and federal research opportunities. FDA reform.
Seek approval for regulatory support; FY25 appropriations; education about the microbiome and federal research opportunities. FDA reform.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Medicare and Medicaid Reform.
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY25 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELUSYS THERAPEUTICS, INC via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · RR
Advocacy for medical countermeasure funding and support
ATEA PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Support for medical/disease research.
Support for medical/disease research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2024 · second_quarter · 2T
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PSYCHEDELIC MEDICINE COALITION via THE CONAFAY GROUP, LLC
2024 · second_quarter · 2T
Education & Advocacy for issues related to alternative treatments for mental health issues and research in treating behavioral health challenges.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Support for biomedical research.
Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Seek approval for regulatory support; FY24 appropriations; education about the microbiome and federal research opportunities.
Seek approval for regulatory support; FY24 appropriations; education about the microbiome and federal research opportunities.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ATEA PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Support for medical/disease research.
Support for medical/disease research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Medical countermeasure and supply management.
Medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PSYCHEDELIC MEDICINE COALITION via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Education & Advocacy for issues related to alternative treatments for mental health issues and research in treating behavioral health challenges.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Seek approval for regulatory support; education about the microbiome and federal research opportunities.
Seek approval for regulatory support; education about the microbiome and federal research opportunities.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Pharmaceutical research.
Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIFESCIENCE LOGISTICS via THE CONAFAY GROUP, LLC
2024 · first_quarter · RR
Medical countermeasure management.
Medical countermeasure management.
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Medicare and Medicaid Reform.
Pharmaceutical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATEA PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Support for medical/disease research.
Support for medical/disease research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PSYCHEDELIC MEDICINE COALITION via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Education & Advocacy for issues related to alternative treatments for mental health issues and research in treating behavioral health challenges.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
PARATEK PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · 4T
Procurement of novel antibiotic.
Procurement of novel antibiotic.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
LUNGPACER MEDICAL USA, INC via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · 4T
Seek support for research and development funding.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Seek approval for regulatory support; education about the microbiome and federal research opportunities.
Seek approval for regulatory support; education about the microbiome and federal research opportunities.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COHERUS BIOSCIENCES via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Lobbying for procurement of American made biosimilars.
Lobbying for procurement of American made biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PARATEK PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Procurement of novel antibiotic.
Procurement of novel antibiotic.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ATEA PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Support for medical/disease research.
Support for medical/disease research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OCUGEN, INC. via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Seek support for R&D funding.
Seek support for R&D funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Pharmaceutical research.
Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG) via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Seek approval for regulatory support; education about the microbiome and federal research opportunities.
Seek approval for regulatory support; education about the microbiome and federal research opportunities.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PSYCHEDELIC MEDICINE COALITION via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Education & Advocacy for issues related to alternative treatments for mental health issues and research in treating behavioral health challenges.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
CORNERSTONE GOVERNMENT AFFAIRS OBO TEXAS MEDICAL CENTER via THE CONAFAY GROUP, LLC
2023 · third_quarter · 3T
Seeking support for research and healthcare.
Seeking support for research and healthcare.
Seeking support for research and healthcare.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LUNGPACER MEDICAL USA, INC via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Seek support for research and development funding.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE COALITION FOR THE ADVANCEMENT OF RESEARCH AND INNOVATION IN TRAUMA (CARIT) via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Support for trauma research.
Support for trauma research.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE